Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Diana R Tamondong-Lachica, Neil Skolnik, John R Hurst, Nathaniel Marchetti, Adrian Paul J Rabe, Maria Montes de Oca & Bartolome R Celli. (2023) GOLD 2023 Update: Implications for Clinical Practice. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 745-754.
Read now
Read now
Marc Miravitlles, Fernando González-Torralba, Cristina Represas-Represas, Xavier Pomares, Eduardo Márquez-Martín, Cruz González, Carlos Amado, Carles Forné, Soledad Alonso, Bernardino Alcázar, Miriam Barrecheguren, Juan María Jurado Mirete & Elsa Naval. (2022) Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1577-1587.
Read now
Read now
Marc Miravitlles, Miguel Roman-Rodríguez, Xavier Ribera, John Ritz & José Luis Izquierdo. (2022) Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 245-258.
Read now
Read now
Carlos Balmaceda, Manuel A. Espinoza, Tomas Abbott & Anne Peters. (2022) Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Review of Pharmacoeconomics & Outcomes Research 22:5, pages 743-751.
Read now
Read now
Laura Mendoza, María Montes de Oca, María Victorina López Varela, Alejandro Casas, Alejandra Ramírez-Venegas, Ana López, Luis Ugalde, Fernando C. Wehrmeister, Filip Surmonti, Ana M. B. Menezes & Marc Miravitlles. (2021) Physical Activity Levels and Associated Factors in a Latin American COPD Population of Patients. The LASSYC Study. COPD: Journal of Chronic Obstructive Pulmonary Disease 18:4, pages 393-400.
Read now
Read now
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Gabriella Matera, Mario Cazzola & Paola Rogliani. (2020) Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Review of Respiratory Medicine 14:6, pages 621-635.
Read now
Read now
Chad Moretz, Ashley L Cole, George Mu, Benjamin Wu, Amy Guisinger, Yunhao Liu, Beth Hahn & Lee Baylis. (2020) Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2207-2215.
Read now
Read now
Chloe I Bloom, Ian Douglas, Omar S Usmani & Jennifer K Quint. (2020) Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 701-710.
Read now
Read now
Johanna Sulku, Christer Janson, Håkan Melhus, Andrei Malinovschi, Björn Ställberg, Kristina Bröms, Marieann Högman, Karin Lisspers, Margareta Hammarlund-Udenaes & Elisabet I Nielsen. (2019) A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2451-2460.
Read now
Read now
Articles from other publishers (16)
Sanjay SethiSwetha R PalliLindsay G S BengtsonErin K BuysmanBrendan ClarkAndrew SargentAsif ShaikhGary T Ferguson. (2023) Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. Journal of Managed Care & Specialty Pharmacy 29:7, pages 791-806.
Crossref
Crossref
Subash Heraganahally, Timothy P Howarth, Siji Issac, Angus Lloyd, Shiidheshwar J Ravichandran, Asanga Abeyaratne & Bhavini Patel. (2023) Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study. BMJ Open Respiratory Research 10:1, pages e001508.
Crossref
Crossref
Marc Miravitlles, Tomotaka Kawayama & Michael Dreher. (2022) LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. Journal of Clinical Medicine 11:22, pages 6623.
Crossref
Crossref
X. Flor-Escriche, A. Sanz Bas, S. Álvarez Álvarez, V. Zamora Putin & M. Monteagudo Zaragoza. (2022) Riesgos, fenotipos y comparación de tratamiento de EPOC en atención primaria según guías GOLD y GesEPOC. Medicina de Familia. SEMERGEN 48:8, pages 101839.
Crossref
Crossref
Masato Muraki, Yuki Kunita, Ken Shirahase, Ryo Yamazaki, Soichiro Hanada, Hirochiyo Sawaguchi & Yuji Tohda. (2021) A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Maria Montes de Oca1, Maria Victorina Lopez Varela2, Ana Maria B. Menezes3, Fernando C. Wehrmeister3, Larissa Ramirez4 & Marc Miravitlles5. (2021) Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study. Jornal Brasileiro de Pneumologia, pages e20210156.
Crossref
Crossref
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez & Gerard Urrútia. (2021) Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. European Respiratory Review 30:160, pages 210075.
Crossref
Crossref
Kartik Deshmukh & Arjun Khanna. (2021) Single inhaler triple therapy in COPD – all that glitters is not gold. Monaldi Archives for Chest Disease 91:2.
Crossref
Crossref
Mònica Monteagudo, Alexa Nuñez, Iryna Solntseva, Nafeesa Dhalwani, Alison Booth, Miriam Barrecheguren, Dimitra Lambrelli & Marc Miravitlles. (2021) Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. Archivos de Bronconeumología 57:3, pages 205-213.
Crossref
Crossref
Mònica Monteagudo, Alexa Nuñez, Iryna Solntseva, Nafeesa Dhalwani, Alison Booth, Miriam Barrecheguren, Dimitra Lambrelli & Marc Miravitlles. (2021) Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. Archivos de Bronconeumología (English Edition) 57:3, pages 205-213.
Crossref
Crossref
Swetha R. PalliMonica FrazerMary DuCharmeAmi R. BuikemaAmy J. AndersonJessica Franchino-Elder. (2020) Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1363-1374.
Crossref
Crossref
María Montes de Oca, Maria Victorina López Varela, Agustín Acuña, Eduardo Schiavi, Alejandro Casas, Antonio Tokumoto, Carlos A. Torres Duque, Alejandra Ramírez-Venegas, Gabriel García, Aquiles Camelier, Miguel Bergna, Mark Cohen, Efraín Sanchez-Angarita, Santiago Guzmán, Karen Czischke, Manuel Barros & Alejandra Rey. (2020) Incorporando nuevas evidencias sobre medicamentos inhalados en la EPOC. Asociación Latinoamericana de Tórax (ALAT) 2019. Archivos de Bronconeumología 56:2, pages 106-113.
Crossref
Crossref
Maria Montes de Oca, Maria Victorina López Varela, Agustín Acuña, Eduardo Schiavi, Alejandro Casas, Antonio Tokumoto, Carlos A. Torres Duque, Alejandra Ramírez-Venegas, Gabriel García, Aquiles Camelier, Miguel Bergna, Mark Cohen, Efraín Sanchez-Angarita, Santiago Guzmán, Karen Czischke, Manuel Barros & Alejandra Rey. (2020) Incorporating new evidence on inhaled medications in COPD. The latin American chest association (ALAT) 2019. Archivos de Bronconeumología (English Edition) 56:2, pages 106-113.
Crossref
Crossref
Swetha R Palli, Ami R Buikema, Mary DuCharme, Monica Frazer, Shuchita Kaila & Timothy Juday. (2019) Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research 8:15, pages 1299-1316.
Crossref
Crossref
Marc Miravitlles, Vladimir Koblizek, Cristina Esquinas, Branislava Milenkovic, Adam Barczyk, Ruzena Tkacova, Attila Somfay, Kirill Zykov, Neven Tudoric, Kosta Kostov, Zuzana Zbozinkova, Michal Svoboda, Jurij Sorli, Alvils Krams & Arschang Valipour. (2019) Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study. Respiratory Medicine 150, pages 141-148.
Crossref
Crossref
Luigino Calzetta, Mario Cazzola, Maria Gabriella Matera & Paola Rogliani. (2019) Adding a LAMA to ICS/LABA Therapy. Chest 155:4, pages 758-770.
Crossref
Crossref